Ainos and Merdury to Explore Phase 3 Study of VELDONA Drug Candidate

(24/7 MARKET NEWS) – Ainos, Inc. (NASDAQ: AIMD) announced, this morning, that it signed a Memorandum of Understanding  with Merdury Biopharmaceutical to jointly explore and develop a strategic business relationship.

Ainos is trading at $0.9893, up $0.2393 (+31.91%), on 140 thousand premarket shares.

Its 52-week trading range is $0.5539 to $18.00. It’s now trading at price levels last seen in November and if it can break through the $1.25 resistance, on strong trading volume, its setup is favorable for a potential run to $1.50 and possibly even to $2+.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist